
FIG. 1 A

FIG. 1 B







FIG. 2

Figure 3


no INXN-1001
+INXN-1001
LLC cells
4T1 cells
mIFNα ELISA
mIL12 ELISA
0
200
400
600
0
1000
2000
3000
4000
0
5000
10000
15000
0
500
1000
1500
2000
mINFα (pg/ml)
mIL12 (pg/ml)
Ad-RTS-mIFNα
Ad-RTS-mIL12
Ad-RTS-mIFNα
Ad-RTS-mIL-12



LLC model
4T1 model
Controls
Ad-RTS-IL12
Ad-RTS-IL12 + INXN-1001
Ad-RTS-IFNα + INXN-1001
Ad-RTS-IL12+Ad-RTS-IFNα +INXN-1001
tumor volume (mm3)
days post tumor inoculation
70%
96%
55%
80%

Figure 4

Figure 5



Intra-tumor
Serum
mIL12
mIFNα
Controls
Ad-RTS-IL-12 or AdRTS-IFNα
Ad-RTS-IL-12 + INXN-1001
Ad-RTS-IFNα + INXN-1001
Ad-RTS-IL-12 +Ad-RTS-IFNα + INXN-1001
5
505
1005
mIL-12 (pg/mg total protein)
5
55
105
mINFα (pg/mg total protein)
205
405
605
mIL-12 (pg/ml)
25
45
65
85
mINFα (pg/ml)

Figure 6





LLC
Mock
Ad-RTS-IL-12/
Ad-RTS-IFNa
Ad-RTS-IFNa
Ad-RTS-IL-12
DMSO
INXN-1001
Relative Cell Number
H-2Kb Fluoresence Intensity (Log)
LLC
PBS
Ad-RTS-mIL-12
Ad-RTS-mIFNα
Ad-RTS-mIL-12/
Ad-RTS-mIFNα
DMSO
INXN-1001
% MHC Class I (H-2K^b) Positive
0
20
40
60
80

FIG. 7A




Vector 0034A

FIG. 7B




Vector 0034-B

FIG. 7C



Vector 0034C

FIG. 7D



Vector 0034D

FIG. 8



43535 + ligand
43537 + ligand
Control - ligand
80
70
60
50
40
30
%HCT
Normal C3H/H HCT range
0
7
14
21
28
35
42
50
57
64
71
85
Days

FIG. 9



43535
43537
Control
% HCT
HuEPO mU/ml
AAV-HuEPO IM
Days
Ligand removed
Ligand removed

FIG. 10




43535
43537
Control
% HCT
HuEPO mU/ml
AAV-HuEPO IM
Days
Ligand removed
Ligand removed

FIG. 11



FIGS. 12A And 12B




FIG. 13



18-0
18-50
18-100
18-250
18-1000
Saline - 1000
Saline -18-0
% HCT
HuEPO mU/ml
85
75
65
55
45
35
0
7
14
21
28
35
Days
AAV-HuEPO IM
Ligand removed

FIG. 14




HuEPO DNA + Hy + Lig.
HuEPO + Hy - Lig.
HuEPO - Hy + Lig.
Saline + Lig.
rProtein + Lig.
HuEPO mU/ml
% HCT
Normal C3H/H HCT range
800
80
8
70
60
50
40
30
20
0
8
15
22
29
36
42
Days
43715 IM-EP
43715 IM-EP

FIG. 15


Intramuscular Delivery of EPO DNA
day 0
day 4
day 7
%HCT
80
75
70
65
60
55
50
45
40
35
30
Normal mouse HCT range
Epo -Hy
Epo +Hy
Control DNA